Amneal Pharmaceuticals (NYSE:AMRX) had its target price lowered by analysts at Raymond James from $5.00 to $4.00 in a note issued to investors on Thursday, Stock Target Advisor reports. The brokerage currently has an “outperform” rating on the stock. Raymond James’ target price points to a potential upside of 46.52% from the company’s current price.
Several other research firms also recently weighed in on AMRX. Barclays set a $5.00 target price on Amneal Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, July 11th. BMO Capital Markets decreased their target price on Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating for the company in a research report on Tuesday, August 6th. Guggenheim began coverage on Amneal Pharmaceuticals in a research report on Thursday, September 12th. They set a “sell” rating and a $2.50 target price for the company. Royal Bank of Canada downgraded Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $11.00 to $6.00 in a research report on Thursday, July 11th. Finally, SunTrust Banks reiterated a “buy” rating and set a $5.00 target price on shares of Amneal Pharmaceuticals in a research report on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.59.
AMRX traded up $0.08 during trading on Thursday, reaching $2.73. The company had a trading volume of 1,428,900 shares, compared to its average volume of 1,461,225. The stock has a market cap of $792.59 million, a P/E ratio of 2.87, a PEG ratio of 0.99 and a beta of 1.48. The business has a 50 day simple moving average of $3.11 and a 200-day simple moving average of $5.44. Amneal Pharmaceuticals has a 52 week low of $2.27 and a 52 week high of $20.40. The company has a quick ratio of 1.41, a current ratio of 2.17 and a debt-to-equity ratio of 3.66.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.09). The company had revenue of $378.30 million during the quarter, compared to the consensus estimate of $403.90 million. Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The firm’s quarterly revenue was down 20.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.28 earnings per share. As a group, equities research analysts expect that Amneal Pharmaceuticals will post 0.31 EPS for the current fiscal year.
In other news, SVP Pradeep Bhadauria purchased 30,000 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were purchased at an average price of $2.41 per share, for a total transaction of $72,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ted C. Nark purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were purchased at an average price of $2.39 per share, for a total transaction of $119,500.00. The disclosure for this purchase can be found here. 25.92% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in AMRX. Fox Run Management L.L.C. purchased a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $177,000. Appleton Partners Inc. MA purchased a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $254,000. SG Americas Securities LLC purchased a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $1,906,000. Swiss National Bank increased its stake in shares of Amneal Pharmaceuticals by 2.1% during the second quarter. Swiss National Bank now owns 171,200 shares of the company’s stock valued at $1,228,000 after buying an additional 3,600 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $368,000. Hedge funds and other institutional investors own 35.01% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Article: How is the LIBOR rate calculated?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.